Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Relatlimab + Nivolumab for Lymphoma
Recruiting1 awardPhase 1 & 2
Austin, Texas
This trial is testing two drugs, relatlimab and nivolumab, in children and young adults whose lymphoma has come back or didn't respond to other treatments. These drugs help the immune system recognize and attack cancer cells. The study aims to see if this combination is safe and effective. Nivolumab has demonstrated clinical benefits in multiple tumors, including classical Hodgkin lymphoma.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service